Clopidogrel decreases arteriovenous fistula thrombosis but does not improve fistula maturation

Area of Science:

• Nephrology
• Vascular Surgery
• Pharmacology

Background:

• Arteriovenous fistula (AVF) creation is crucial for hemodialysis access.
• Fistula thrombosis is a common complication, leading to access failure.
• Evaluating pharmacological interventions to prevent thrombosis is essential.

Discussion:

• A randomized, double-blind, placebo-controlled trial assessed clopidogrel's efficacy post-AVF creation.
• Patients received clopidogrel (loading dose followed by daily maintenance) or placebo for six weeks.
• The study aimed to determine if clopidogrel reduces fistula thrombosis and improves dialysis access.

Key Insights:

• Clopidogrel significantly decreased the rate of AV fistula thrombosis compared to placebo (12.2% vs. 19.5%, P = 0.018).
• Despite reduced thrombosis, clopidogrel did not lead to a significant difference in achieving a usable dialysis access.
• The secondary endpoint of successful dialysis access was not improved by clopidogrel treatment.

Outlook:

• Routine use of clopidogrel after AV fistula creation is not clinically beneficial for improving dialysis access.
• Further research may explore alternative antiplatelet strategies or patient subgroups who might benefit.
• Optimizing AV fistula patency remains a critical goal in hemodialysis patient care.